Codexis, Inc. (CDXS)
CDXS Price and Sentiment
CDXS Latest news
Codexis is leveraging its core technology to create more effective life science tools.
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India2021-10-18 08:00
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients (APIs), and RC2 Pharma Connect, LLC, a U.S.-based leading pharmaceutical manufacturing representative, to license and manufacture for internal use a Codexis' proprietary enzyme used in the manufacturing process for sitagliptin, a leading API in the treatment of diabetes. Under the agreement, Almelo will be responsible for the development, scale-up, and establishment of a commercial manufacturing process for sitagliptin incorporating Codexis' proprietary enzyme technology. Upon completion, the enzyme's manufacturing will be established at Almelo's API manufacturing site to enable further cost reduction. RC2's role in the collaboration will be to leverage its relationships with global drug product partners to establish do
If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet.
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United States and Canada, to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active pharmaceutical ingredient (API) in Merck's JANUVIA® and one of the active ingredients in Merck's JANUMET®.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences.
Codexis Confirms Receipt of Follow-on Orders for Proprietary Enzyme Product from Undisclosed Global Pharmaceutical Company2021-08-25 16:05
Orders Support Company's Recently Increased 2021 Guidance Orders Support Company's Recently Increased 2021 Guidance
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript